Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmathen

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

EU flag

EMA initiative aims to fast-track important new drugs

Hopes PRIME programme will foster greater cooperation with industry 

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

The EMA’s literature screening service and pharma

Complexities and new potential in pharmacovigilance

- PMLiVE

Harvoni cleared for broader use in hepatitis C

Gilead Sciences’ drug wins US approval for use in liver transplant patients

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

Digital roundup

Genzyme, Merck, the forthcoming EU clinical trials portal and more

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Gilead’s John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links